US 11,912,760 B2
Doppel-targeting antibodies
Youngro Byun, Seoul (KR); Ha Kyeong Lee, Seoul (KR); So Young Choi, Sejong-si (KR); So Ra Park, Cheongju-si (KR); Se Ra Lee, Sejong-si (KR); and Seung Il Baek, Seongnam-si (KR)
Assigned to PHAROSGEN CO., LTD, Seoul (KR)
Filed by PHAROSGEN CO., LTD, Seoul (KR)
Filed on Jun. 17, 2021, as Appl. No. 17/350,763.
Claims priority of application No. 10-2021-0019883 (KR), filed on Feb. 15, 2021.
Prior Publication US 2022/0267422 A1, Aug. 25, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); G01N 33/53 (2006.01); A61K 49/00 (2006.01); C07K 16/46 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); G01N 33/68 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 35/00 (2018.01); G01N 33/68 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 27 Claims
 
1. A doppel-targeting molecule that binds to doppel, wherein the doppel targeting molecule comprises a heavy chain variable region and a light chain variable region, wherein:
(a) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 58; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 59; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 60; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 1; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 3;
(b) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 61; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 62; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 63; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 4; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 6;
(c) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 64; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 65; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 66; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 7; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 8; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 9;
(d) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 67; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 68; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 69; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 10; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 11; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 12;
(e) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 70; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 71; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 72; and the light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO: 13; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 14; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 15;
(f) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 73; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 74; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 75; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 16; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 17; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 18;
(g) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 76; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 77; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 78; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 19; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 20; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 21;
(h) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 79; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 80; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 81; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 22; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 23; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 24;
(i) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 82; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 83; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 84; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 25; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 26; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 27;
(j) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 85; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 86; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 87; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 28; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 29; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 30;
(k) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 88; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 89; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 90; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 31; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 32; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 33;
(l) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 91; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 92; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 93; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 34; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 35; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 36;
(m) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 94; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 95; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 96; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 37; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 38; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 39;
(n) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 97; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 98; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 99; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 40; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 41; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 42;
(o) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 100; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 101; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 102; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 43; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 44; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 45;
(p) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 103; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 104; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 105; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 46; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 47; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 48;
(q) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 106; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 107; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 108; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 49; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 50; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 51;
(r) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 109; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 110; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 111; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 52; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 53; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 54;
(s) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO: 112; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 113; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 114; and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO: 55; a CDRL2 comprising the amino acid sequence of SEQ ID NO: 56; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 57; and
doppel-binding fragments of any thereof.